Q2 Earnings Estimate for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Recursion Pharmaceuticals in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.29) per share for the quarter, down from their prior forecast of ($0.27). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.35) EPS.

RXRX has been the subject of several other research reports. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $5.84 on Monday. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $6.00. The stock has a market capitalization of $2.37 billion, a P/E ratio of -3.30 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same quarter in the prior year, the business posted ($0.39) EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Ensign Peak Advisors Inc lifted its stake in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after purchasing an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after acquiring an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after acquiring an additional 1,907 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after acquiring an additional 2,026 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.